RxDoctor Payments Data

Jesus Vargas, MD

Internal Medicine · Harrisburg, PANPI 1487017059

Payments from drug & device makers

$41,590in general payments, 2019–2025

Across 72 payments — averaging $577.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$23K
  • Lilly USA, LLC$15K
  • Novartis$3K
  • Abbott$306
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$285
  • E.r. Squibb & Sons, L.L.C.$112
  • plus $138 from 4 others
$5,625in research payments, 2019–2025

Across 1 payment — averaging $5625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$6K

What the payments were for

  • Consulting fees$1,7164%
  • Speaking & faculty fees$35,85186%
  • Travel & lodging$2,1455%
  • Food & beverage$1,8694%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,590 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,770
Medicare patients
302
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin228$132,670
EliquisApixaban91$66,511
EntrestoSacubitril/Valsartan107$49,112
XareltoRivaroxaban23$19,264
BrilintaTicagrelor29$14,774
TradjentaLinagliptin11$5,771
Metoprolol Succinate295$3,559
Bumetanide103$2,998
Prasugrel Hcl34$2,978
Amiodarone Hcl108$2,183
Atorvastatin Calcium123$1,292
Furosemide266$775
Isosorbide Dinitrate11$702
Nifedipine ErNifedipine28$565
Isosorbide Mononitrate ErIsosorbide Mononitrate76$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$23,419$138,442239 claims
NovartisEntresto$2,508$49,112107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →